Atossa Therapeutics, Inc. (ATOS)
Pre-market:
| Previous close | 1.3000 |
| Open | 1.3000 |
| Bid | 1.2900 x 500 |
| Ask | 1.3400 x 600 |
| Day's range | 1.2700 - 1.3700 |
| 52-week range | 0.6200 - 2.3100 |
| Volume | |
| Avg. volume | 1,997,820 |
| Market cap | 165.999M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model i
- GlobeNewswire
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person
- GlobeNewswire
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Ato
